pISSN 1226-6051
eISSN 2508-786X

Table. 6.

Table. 6.

Outcomes of users of rivaroxaban vs. dabigatran

Rivaroxaban user (n=721) Matched dabigatran user (n=721) Hazard Ratio(95% CI)


Events(%) Person-years(PYs) IR/100PYs Events(%) Person-years(PYs) IR/100PYs
MACCE 11(1.53) 229.2 4.8 11(1.53) 245.21 4.49 1.05(0.45-2.43)
Ischemic stroke/systemic embolism 2(0.28) 230.44 0.87 2(0.28) 246.81 0.81 1.09(0.15-7.94)
Myocardial infarction 5(0.69) 230.13 2.17 9(1.25) 245.83 3.66 0.58(0.19-1.73)
Cardiac death 4(0.55) 230.31 1.74 1(0.14) 247.28 0.4 4.13(0.46-37.54)
Bleeding 19(2.64) 227.35 8.36 9(1.25) 245.12 3.67 2.25(1.01-4.99)
Intracranial bleeding 1(0.14) 230.69 0.43 0(0) 247.44 0 NA
Gastrointestinal bleeding 18(2.50) 227.49 7.91 9(1.25) 245.12 3.67 2.13(0.95-4.76)

MACCE, major adverse cerebro-cardiovascular events; IR, incidence rate; PY, person-years; CI, confidence interval

Korean J Clin Pharm 2022;32:37-46 https://doi.org/10.24304/kjcp.2022.32.1.37
© 2022 Korean J Clin Pharm